Overview

This trial is active, not recruiting.

Condition polycystic ovary syndrome
Sponsor Ankara Education and Research Hospital
Trial identifier NCT01644305, 3849

Summary

The purpose of this study is to determine the plasma levels of GDF-9 and GDF-15, and their association with bone and cardiovascular parameters in patients with Polycystic Ovary Syndrome.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective cross-sectional
Arm

Primary Outcomes

Measure
The association of GDF 9 AND GDF 15 with bone and cardiovascular parameters in women with polycystic ovary syndrome
time frame:

Eligibility Criteria

Female participants from 25 years up to 35 years old.

Inclusion Criteria: - Female patients at ages 25-35 diagnosed with polycystic ovarian syndrome and idiopathic hirsutism Exclusion Criteria: - acute infectious disease, a thyroid, pituitary, nutritional, inflammatory, hepatic, renal, or neoplastic disorder; history of cardiovascular disease or pulmonary embolism; a family history of coronary artery disease; smoking history; hypertension; diabetes mellitus; use of oral contraceptives, anti-androgens and drugs known to interfere with cytokine release, such as corticosteroids, immunosuppressors, or nonsteroidal antiinflammatory drugs. any medication known to affect hormonal or metabolic parameters.

Trial information was received from ClinicalTrials.gov and was last updated in July 2012.
Information provided to ClinicalTrials.gov by Ankara Education and Research Hospital.